ARCTURUS THERAPEUTICS HOLDIN
ARCTNASDAQTrading Snapshot
- Day Range
- $13.62 – $13.96
- 52-Week Range
- $5.50 – $24.17
- Volume
- $2.69B
- Avg Volume
- $2.55B
- Shares Outstanding
- 28.4M
- Next Earnings
- Oct 19, 2026
Fundamentals Snapshot
- Annual Revenue
- $67M
- Last Q Revenue
- $3M
- P/E Ratio
- -4.2
- P/S Ratio
- 16.7x
- EPS (TTM)
- $-3.28
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +1.4%
Why Investors Own ARCT
- ✓High-growth profile — revenue up +53.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 57% gross margin and 15% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ARCTURUS THERAPEUTICS HOLDIN
ARCT
StockOtter · stockotter.spaceAbout ARCTURUS THERAPEUTICS HOLDIN
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
ARCTURUS THERAPEUTICS HOLDIN tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift ARCT price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
ARCTURUS THERAPEUTICS HOLDIN announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.